| abstract |
A porphycene having structure (I) wherein each R?1 is, independently, (a) -(CH2?)n?-X, where n=1-4, X is OR?2 and R?2 is C1-6? alkyl, aralkyl or aryl; CN; OH; OSO2?R?2; NH2?; NHR?2; NR?22?; SH; SR?2; S(O)1-2?R?2; COOH; CO2?R?2; C(O)NH2?; C(O)NHR?2; C(O)NR?22?; halogen; or CHO; (b) -(CH2?)m?CH=CH2? where m is 0-2; or (c) -(CH2?)n?-O-G where G is a mono- or oligosaccharide; (d) -(CH2?)2n?-X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or -Y-(CH2?)n?-porphycene?2 (porphycene?2 being a compound of the same structure and Y is a direct bond; -O-; or -CH=CH2?); or (e) where one, two or three of the substituents R?1 are C1-6? alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof. The porphycene compounds and pharmaceutical compositions containing the compounds are useful in photodynamic therapy treatment of tumors and psoriasis. |